This Trial Evaluates Safety, Pharmacokinetic Profile and Anti-viral Response of BI 207127 and BI 201335 for Patients With Chronic Hepatitis C

Exclusion Criteria

• •Hepatitis C infection of mixed genotype (1/2, 1/3, and 1/4) diagnosed by genotypic testing at screening
• •Human immunodeficiency virus (HIV) co-infection
• •Decompensated liver disease, or history of decompensated liver disease
• •Body weight \< 40 or \> 125 kg at screening
• •Hemoglobin \<12.0g/dL for women and \<13.0g/dL for men at screening
• •White blood cell count \<3000 cells/mm3 at screening
• •Absolute neutrophil count \< 1,500 cells/mm3 at screening
• •Platelet count \< 90,000 /mm3 at screening
• •Serum creatinine \> 1.5xUpper Limit of Normal range(ULN) or creatinine clearance =50 mL/min at screening